| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,784 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,025 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schott Robert J. |
SVP, Head of Development |
• – – |
2022-02-12 |
4 |
D |
$5.76 |
$31,467 |
D/D |
(5,463) |
34,537 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-28 |
4 |
S |
$8.51 |
$23,522 |
I/I |
(2,764) |
24,152,466 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-27 |
4 |
S |
$8.56 |
$5,136 |
I/I |
(600) |
24,155,230 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-23 |
4 |
S |
$8.55 |
$694,530 |
I/I |
(81,187) |
24,155,830 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-09 |
4 |
S |
$8.56 |
$202,541 |
I/I |
(23,660) |
24,237,017 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-08 |
4 |
S |
$8.64 |
$654,828 |
I/I |
(75,814) |
24,260,677 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-07 |
4 |
S |
$8.52 |
$444,437 |
I/I |
(52,178) |
24,336,491 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-02 |
4 |
S |
$8.51 |
$15,943 |
I/I |
(1,874) |
24,388,669 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-12-01 |
4 |
S |
$8.52 |
$6,223 |
I/I |
(730) |
24,390,543 |
|
- |
|
| Biogen Ma Inc. |
10% Owner |
– – • |
2021-11-26 |
4 |
S |
$8.60 |
$248,434 |
I/I |
(28,884) |
24,391,273 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2021-10-29 |
4 |
D |
$8.12 |
$1,137 |
D/D |
(140) |
54,455 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2021-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
54,595 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & SecretaryO |
• – – |
2021-08-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
47,095 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Business Officer |
• – – |
2021-06-25 |
4 |
D |
$12.02 |
$138,531 |
D/D |
(11,525) |
129,294 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CFO, PFO and PAO |
• – – |
2021-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
49,827 |
|
- |
|
| Duraibabu Prathyusha |
VP, PFO and PAO |
• – – |
2021-04-25 |
4 |
D |
$11.71 |
$7,752 |
D/D |
(662) |
40,128 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2021-04-25 |
4 |
D |
$11.71 |
$9,497 |
D/D |
(811) |
62,496 |
|
- |
|
| Duraibabu Prathyusha |
VP, PFO and PAO |
• – – |
2021-03-25 |
4 |
D |
$12.27 |
$4,233 |
D/D |
(345) |
40,790 |
|
- |
|
| Loeb Gary |
EVP, General Counsel & Sec. |
• – – |
2021-03-23 |
4 |
S |
$13.10 |
$230,042 |
D/D |
(17,524) |
83,238 |
|
- |
|
| Loeb Gary |
EVP, General Counsel & Sec. |
• – – |
2021-03-23 |
4 |
OE |
$11.02 |
$132,031 |
D/D |
11,981 |
100,762 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific OfficerO |
• – – |
2021-03-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
63,307 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Business Officer |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
140,000 |
|
- |
|
| Parker H Stewart |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
31,200 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
98,199 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2021-02-25 |
4 |
D |
$11.19 |
$87,047 |
D/D |
(7,779) |
58,199 |
|
- |
|
1096 Records found
|
|
Page 5 of 44 |
|
|
0.04 (6.83%) 
